<DOC>
	<DOCNO>NCT00106262</DOCNO>
	<brief_summary>This study conduct evaluation two chemotherapy drug , Velcade Irinotecan , woman advance , recurrent , metastatic cervical cancer , vaginal cancer , vulvar cancer . Patients cervical cancer may receive platinum-containing treatment systemic therapy without radiation , require .</brief_summary>
	<brief_title>Study Velcade Irinotecan Advanced Cervical , Vulvar , Vaginal Cancer</brief_title>
	<detailed_description>This phase 2 study . Patients advance metastatic histologically document squamous cell carcinoma , adenocarcinoma , adenosquamous cancer originate cervix , vagina , vulva eligible . Measurable disease either clinical exam radiography also require . Patients receive cisplatin-based chemoradiation definitive treatment local disease eligible . Patients must one prior platinum-based chemotherapy regimen metastatic setting . Patients present distant metastatic disease ( beyond pelvis ) eligible , long eligible high priority study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Inclusion Criteria Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( ie , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . age &gt; 18 Karnofsky performance status &gt; 60 % Measurable disease clinical exam RECIST criterion One prior platinumbased systemic chemotherapy regimen advance disease allow require . Chemotherapy administer radiosensitizer conjunction primary radiotherapy consider systemic chemotherapy regimen also allow . Patients eligible high priority study exclude . Life expectancy &gt; 6 week Peripheral neuropathy ≤ Grade 2 CTC 3.0 criterion Women childbearing potential must negative pregnancy test Adequate hematopoietic function define : ANC ≥ 1500/mm3 ; Platelets ≥ 100,000/mm3 ; Hemoglobin ≥ 8 g/dL . Adequate renal hepatic function define : Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ; SGOT ≤ 2.5 time ULN ; Alkaline phosphatase ≤ 2.5 time ULN ; Creatinine ≤ 2 time ULN . Exclusion Criteria Patient hypersensitivity bortezomib , boron mannitol . Female subject pregnant breastfeeding . Patient receive investigational drug 14 day enrollment Serious medical psychiatric illness likely interfere participation clinical study . Prior treatment CAMPTOSAR VELCADE More one prior treatment metastatic disease . Concurrent uncontrolled illness Ongoing active infection History active secondary cancer within last 5 year , except superficial basal cell skin cancer Psychiatric illness social situation would preclude study compliance .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>advanced cervical cancer</keyword>
	<keyword>metastatic cervical cancer</keyword>
</DOC>